

Maxine Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5801779/publications.pdf>

Version: 2024-02-01

100
papers

5,352
citations

101543

36
h-index

91884

69
g-index

101
all docs

101
docs citations

101
times ranked

7020
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. <i>Clinical Cancer Research</i> , 2022, 28, 748-755.	7.0	9
2	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 130.e17-130.e24.	1.6	4
3	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. <i>European Urology Oncology</i> , 2021, 4, 66-72.	5.4	20
4	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	12.8	84
5	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	2.2	63
6	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e92-e99.	1.9	30
7	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	16.8	263
8	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	16.8	230
9	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 413-418.	1.3	8
10	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021, 4, 396-404.	5.4	30
11	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 74.e13-74.e20.	1.6	6
12	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 410-418.	3.9	17
13	Prostate cancer management costs vary by disease stage at presentation. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 564-566.	3.9	2
14	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	30.7	488
15	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2020, 4, 2430-2438.	5.2	54
16	Association of Affordable Care Act-related Medicaid expansion with variation in utilization of surgical services. <i>American Journal of Surgery</i> , 2020, 220, 441-447.	1.8	7
17	Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. <i>BJU International</i> , 2020, 126, 9-10.	2.5	11
18	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20224.	3.7	14

#	ARTICLE	IF	CITATIONS
19	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. <i>Journal of Oncology Practice</i> , 2019, 15, e547-e559.	2.5	8
20	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 593-599.	3.9	8
21	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. <i>European Urology Oncology</i> , 2019, 2, 349-354.	5.4	6
22	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 125-136.	3.9	53
23	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. <i>Annals of Surgical Oncology</i> , 2019, 26, 297-305.	1.5	20
24	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019, 125, 1319-1329.	4.1	20
25	Epidemiology of Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 74-84.	1.9	917
26	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , 2019, 5, 474-481.	3.1	44
27	Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. <i>European Urology Focus</i> , 2019, 5, 77-80.	3.1	43
28	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019, 201, 735-741.	0.4	31
29	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1049-1058.	4.9	21
30	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2018, 200, 573-581.	0.4	31
31	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e7-238.e17.	1.6	21
32	Reassessing the value of high-volume cancer care in the era of precision medicine. <i>Cancer</i> , 2018, 124, 1319-1321.	4.1	20
33	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2018, 199, 1417-1425.	0.4	70
34	Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. <i>BJU International</i> , 2018, 121, 811-818.	2.5	27
35	Comparative effectiveness of robot-assisted vs. open radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 88.e1-88.e9.	1.6	52
36	Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act. <i>JAMA Oncology</i> , 2018, 4, 128.	7.1	20

#	ARTICLE	IF	CITATIONS
37	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e129-e139.	1.9	17
38	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 225.	7.1	58
39	Variation in the use of active surveillance for low-risk prostate cancer. <i>Cancer</i> , 2018, 124, 55-64.	4.1	40
40	Comparative Effectiveness of Transurethral Resection Techniques in the Inpatient Setting for Benign Prostatic Hyperplasia. <i>Urology Practice</i> , 2018, 5, 377-382.	0.5	1
41	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 78.e13-78.e19.	1.6	16
42	State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. <i>Urology</i> , 2018, 112, 56-65.	1.0	7
43	Comparative effectiveness research methodology using secondary data: A starting user's guide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 174-182.	1.6	6
44	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. <i>European Urology</i> , 2018, 73, 445-451.	1.9	43
45	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018, 73, 374-382.	1.9	62
46	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 400.e15-400.e22.	1.6	1
47	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018, 74, 611-620.	1.9	77
48	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. <i>Canadian Urological Association Journal</i> , 2018, 13, 32-37.	0.6	2
49	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018, 36, 1767-1774.	2.2	12
50	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1439-1445.	1.0	32
51	The impact of treatment at minority-serving hospitals on outcomes for bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 492-492.	1.6	0
52	Do accountable care organizations impact prostate cancer screening?. <i>Journal of Clinical Oncology</i> , 2018, 36, 6546-6546.	1.6	0
53	Do accountable care organizations impact prevalence of mammography and colonoscopies among Medicare beneficiaries?. <i>Journal of Clinical Oncology</i> , 2018, 36, e18516-e18516.	1.6	0
54	The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. <i>European Urology</i> , 2017, 72, 14-19.	1.9	128

#	ARTICLE	IF	CITATIONS
55	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 852-860.	1.6	104
56	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. <i>Current Urology Reports</i> , 2017, 18, 15.	2.2	49
57	An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program. <i>Urology</i> , 2017, 103, 91-98.	1.0	27
58	Risk Assessment in Small Renal Masses. <i>Urologic Clinics of North America</i> , 2017, 44, 189-202.	1.8	6
59	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2017, 72, 483-487.	1.9	110
60	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2017, 71, 714-718.	1.9	40
61	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. <i>Journal of Urology</i> , 2017, 198, 1061-1068.	0.4	31
62	Accountable care organizations and the use of cancer screening. <i>Preventive Medicine</i> , 2017, 101, 15-17.	3.4	18
63	Complications After Metastasectomy for Renal Cell Carcinoma—A Population-based Assessment. <i>European Urology</i> , 2017, 72, 171-174.	1.9	44
64	Assessing robot-assisted laparoscopic prostatectomy. <i>Lancet, The</i> , 2017, 389, 799.	13.7	5
65	The association of hypoalbuminemia with early perioperative outcomes — A comprehensive assessment across 16 major procedures. <i>American Journal of Surgery</i> , 2017, 214, 871-883.	1.8	42
66	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. <i>Journal of Urology</i> , 2017, 198, 1295-1300.	0.4	10
67	Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer</i> , 2017, 123, 4346-4355.	4.1	138
68	Reply to C. Buttigliero et al and B. Biswas et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1266-1267.	1.6	0
69	Adverse effects of androgen deprivation therapy on cognitive impairment for men with prostate cancer: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16506-e16506.	1.6	0
70	Accountable care organizations and the use of prostate cancer screening and breast cancer screening.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18308-e18308.	1.6	0
71	Association of Androgen Deprivation Therapy With Alzheimer's Disease: Unmeasured Confounders. <i>Journal of Clinical Oncology</i> , 2016, 34, 2801-2803.	1.6	6
72	Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. <i>BJU International</i> , 2016, 118, 221-229.	2.5	22

#	ARTICLE	IF	CITATIONS
73	Recurrence in renal cell carcinoma: the work is not done. <i>Nature Reviews Urology</i> , 2016, 13, 246-247.	3.8	11
74	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. <i>European Urology Focus</i> , 2016, 2, 3-9.	3.1	7
75	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 293.e1-293.e10.	1.6	43
76	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3267-3275.	1.6	185
77	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. <i>Preventive Medicine</i> , 2016, 89, 140-145.	3.4	63
78	Re: Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. <i>European Urology</i> , 2016, 69, 963-964.	1.9	2
79	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2016, 196, 1090-1095.	0.4	42
80	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016, 34, 3529-3536.	1.6	70
81	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States. <i>JAMA Oncology</i> , 2016, 2, 543.	7.1	5
82	Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations. <i>JAMA Internal Medicine</i> , 2016, 176, 546.	5.1	32
83	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. <i>JAMA Oncology</i> , 2016, 2, 500.	7.1	94
84	Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction. <i>European Urology</i> , 2016, 69, 92-93.	1.9	0
85	External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 283-289.	0.4	19
86	A Surveillance, Epidemiology and End Results (<scp>SEER</scp>) database malfunction: perceptions, pitfalls and verities. <i>BJU International</i> , 2016, 117, 551-552.	2.5	31
87	Assessment of metastasectomy complications in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 619-619.	1.6	0
88	Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report.. <i>Journal of Clinical Oncology</i> , 2016, 34, 450-450.	1.6	0
89	Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, 620-620.	1.6	0
90	The adverse effects of androgen-deprivation therapy: Comparison between gonadotropin-releasing hormone agonists and orchiectomy in the SEER-Medicare population.. <i>Journal of Clinical Oncology</i> , 2016, 34, 304-304.	1.6	0

#	ARTICLE	IF	CITATIONS
91	The influence of physician recommendation on prostate-specific antigen screening. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 424.e1-424.e7.	1.6	28
92	Contemporary incidence and mortality rates of kidney cancer in the United States. <i>Canadian Urological Association Journal</i> , 2014, 8, 247.	0.6	78
93	Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3939-3947.	1.6	246
94	Pediatric Nephrectomy: Incidence, Indications and Use of Minimally Invasive Techniques. <i>Journal of Urology</i> , 2014, 191, 764-770.	0.4	17
95	Testosterone Replacement Therapy Following the Diagnosis of Prostate Cancer: Outcomes and Utilization Trends. <i>Journal of Sexual Medicine</i> , 2014, 11, 1063-1070.	0.6	39
96	Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. <i>European Urology</i> , 2014, 65, 235-241.	1.9	110
97	Population-based Comparative Effectiveness of Salvage Radical Prostatectomy vs Cryotherapy. <i>Urology</i> , 2014, 83, 653-657.	1.0	11
98	In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy. <i>European Urology</i> , 2013, 63, 1107-1114.	1.9	51
99	Statistical Analysis Plans in Observational Research. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 32.	7.4	3
100	Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis. <i>European Urology</i> , 2011, 59, 135-141.	1.9	259